These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8178710)

  • 1. Dose-dependent inhibition of aspartate carbamoyltransferase in peripheral blood mononuclear cells in patients receiving N-(phosphonacetyl)-L-aspartate.
    Grem JL; McAtee N; Drake JC; Steinberg S; Allegra CJ
    Adv Exp Med Biol; 1993; 339():119-23. PubMed ID: 8178710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
    Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
    Grem JL; Yee LK; Schuler B; Hamilton JM; Chen AP; Chabuk C; Grollman F; Grabenc M; Allegra CJ; Takimoto CH
    Ann Oncol; 2001 Nov; 12(11):1581-7. PubMed ID: 11822758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
    Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
    Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
    Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL
    Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of aspartate carbamoyltransferase activity by high performance liquid chromatography.
    Grem JL; Drake JC; Allegra CJ
    Anticancer Drugs; 1993 Oct; 4(5):545-54. PubMed ID: 8292811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
    Hageboutros A; Rogatko A; Newman EM; McAleer C; Brennan J; LaCreta FP; Hudes GR; Ozols RF; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1995; 35(3):205-12. PubMed ID: 7805178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of low-dose PALA in biochemical modulation.
    O'Dwyer PJ
    Pharmacol Ther; 1990; 48(3):371-80. PubMed ID: 2084707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
    Kemeny N; Conti JA; Seiter K; Niedzwiecki D; Botet J; Martin D; Costa P; Wiseberg J; McCulloch W
    J Clin Oncol; 1992 May; 10(5):747-52. PubMed ID: 1569447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Ardalan B; Stridhar K; Reddy R; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Livingstone A
    Int J Radiat Oncol Biol Phys; 1992; 22(3):511-4. PubMed ID: 1735689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Ardalan B; Ucar A; Reddy R; Livingstone AS; Markoe A; Schwade J; Richman SP; Donofrio K
    Cancer; 1994 Oct; 74(7):1869-73. PubMed ID: 8082092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Ardalan B; Sridhar KS; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Fodor M; Livingstone A
    Cancer; 1991 Sep; 68(6):1242-6. PubMed ID: 1873776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
    O'Dwyer PJ; Hudes GR; Colofiore J; Walczak J; Hoffman J; LaCreta FP; Comis RL; Martin DS; Ozols RF
    J Natl Cancer Inst; 1991 Sep; 83(17):1235-40. PubMed ID: 1714507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
    Ardalan B; Singh G; Silberman H
    J Clin Oncol; 1988 Jun; 6(6):1053-8. PubMed ID: 3373260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
    Hageboutros A; Hudes GR; Greene F; LaCreta FP; Brennan J; O'Dwyer PJ
    Invest New Drugs; 1997; 15(2):139-45. PubMed ID: 9220293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
    Jodrell DI; Oster W; Kerr DJ; Canney PA; Yosef H; Steward WP; Kaye SB; Cassidy J
    Eur J Cancer; 1994; 30A(7):950-5. PubMed ID: 7946590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
    Loo TL; Friedman J; Moore EC; Valdivieso M; Marti JR; Stewart D
    Cancer Res; 1980 Jan; 40(1):86-90. PubMed ID: 7349907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of continuous-infusion PALA and 5-FU.
    Ardalan B; Jamin D; Jayaram HN; Presant CA
    Cancer Treat Rep; 1984 Mar; 68(3):531-4. PubMed ID: 6231102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral leukocytes as indicators of the enzymatic effects of N-(phosphonacetyl)-L-aspartic acid (PALA) on human L-aspartate transcarbamoylase (ATCase) activity.
    Kensler TW; Erlichman C; Jayaram HN; Tyagi AK; Ardalan B; Cooney DA
    Cancer Treat Rep; 1980; 64(8-9):967-73. PubMed ID: 7448831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term association of N-(phosphonacetyl)-L-aspartate with bone.
    Ardalan B; Kensler TW; Jayaram HN; Morrison W; Choie DD; Chadwick M; Liss R; Cooney DA
    Cancer Res; 1981 Jan; 41(1):150-6. PubMed ID: 7448755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.